The Drug Enforcement Administration (DEA) and the Substance Abuse and Mental Health Services Administration (SAMHSA) have proposed to further extended flexibilities that allow providers to prescribe controlled substances via telemedicine without first performing an in-person visit. The flexibilities were initially provided during the COVID-19 Public Health Emergency (PHE). This extension, which follows an earlier temporary rule issued in May 2023, authorizes all DEA-registered practitioners to prescribe schedule II-V controlled medications via telemedicine through December 31, 2024, regardless of when the practitioner-patient relationship was established. The DEA anticipates releasing a final rule addressing telemedicine prescription of controlled substances in fall of 2024.